TAB 3
	International multicenter clinical study - The use of preparations containing glycyrhizinic acid
	in dermatology practice - Survey of basic patients data - group Herpes progenitalis recid
	Num	Herpes progenitalis recid	Men	ø Age	Women	ø Age	A	B	C	D	DE	DT	PE	PT	E
	1	creme	T.H.	36	-	-	5	4	0	0	1	1	1	1	0
	2	creme	-	-	E.P.	40	5	5	0	0	1	1	1	1	0
	3	creme	-	-	P.M.	41	5	5	0	0	1	1	1	1	0
	4	creme	P.J.	70	-	-	3	30	0	0	1	2	1	2	0
	5	creme	M.P.	32	-	-	4	5	0	0	1	1	1	1	0
	6	creme	H.A.	33	-	-	4	8	0	0	1	1	1	1	0
	7	creme	J.M.	27	-	-	5	8	0	0	1	1	1	1	0
	8	creme	K.K.	38	-	-	4	5	0	0	1	1	1	1	0
	9	spray	B.V.	36	-	-	5	5	0	0	1	1	1	1	0
	10	spray	-	-	K.B.	31	3	4	0	0	1	1	1	1	0
	11	creme	-	-	K.V.	39	3	6	0	0	1	1	1	1	0
	Summary		-	38,9		37,75	4,18	7,73	-	-	-	-	-	-	-
	Legend
	A - number of aplication/day
	B - duration of aplication/day
	C - Undesirable effects
	D - Relaps
	DE/DT - evaluation of doctor - effect/tolerance
	PE/PT- eavaluation of patient - effect/tolerance
	E - interruption of application
	Effect					Tolerance
	1 - very good					1- very good
	2 - good					2 - good
	3 - no effect					3 - no effect
	4 - degradation					4 - exacerbation
	Graph 5
	International multicenter clinical study - The use of preparations containing glycyrhizinic acid
	in dermatology practice - Survey of basic patients data - group Herpes progenitalis recid
	Graph 6
	International multicenter clinical study - The use of preparations containing glycyrhizinic acid
	in dermatology practice - Survey of basic patients data - group Herpes progenitalis recid